IPO
-
-
-
-
-
-
-
Zymeworks Reports Financial Results for the Second Quarter of 2018
-
-
-
-
-
-
-
Zymeworks (ZYME) Executes License Agreement ohnson & Johnson (JNJ) Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics
-
-
-
-
-
-
-
Zymeworks Reports Second Quarter 2017 Financial Results
-
-
-
-
-
-
-
Zymeworks (ZYME) Reports Q1 Revenues of $0.2M
-
-
-
-
-
-
-
Zymeworks Files Registration Statement For Proposed Initial Public Offering
99,497 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All